References
- Buller J. Dispensing pharmacy in a community oncology practice: Success. Oncologistics. 2006: First Quarter; 9–12
- Garattini S, Bertele V. Efficacy, safety, and cost of new anticancer drugs. Br Med J. 2002: 325(7358); 269–271.
- Calvert H, Jodrell DI, Cassidy J, Harris AL. Efficacy, safety, and cost of new anticancer drugs: Pessimistic conclusion was not justified. Br Med J 2002: 325(7375); 1302.
- Jennett B, Buxton M. When is treatment for cancer economically justified? Discussion paper. J Royal Society of Med. 1990: 83; 25–28.
- Foy R, So J, Rous E, Scarffe JH. Perspectives of commissioners and cancer specialists in prioritizing new cancer drugs: Impact of the evidence threshold. Br Med J. 1999; 318(7181): 456–459.
References
- Brower V. Fast tracking drugs in patients. European Molecular Biology Organization. 2002; 3(1): 14–16.
- Dacogen product information. MGI Pharma, Inc. Bloomington, MN. May 2006.
- Palacio M. FDA approves decitabine for treatment of myelodys-plastic syndromes. Hem/Onc Today. June 2006; 16.
- Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792–799.
- Arranon product information. GlaxoSmithKline. Research Triangle Park, NC. October 2005.
- Weiner LM, Borghaei H. Targeted therapies in solid tumors: Monoclonal antibodies and small molecules. Hum Antibodies. 2006;15(3):103–111.
- Paul MK, Mukhopadhyay AK. Tyrosine kinase—role and significance in cancer. Int J Med Sci. 2004; 1(2):101–115.
- Lin NU, Winer EP. New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors. Breast Cancer Res. 2004; 6(5):204–210.
- Fuerst ML. FDA approves dasatinib for imatinib resistance & intolerance 3 weeks after enthusiastic recommendation from ODAC. Oncology Times. July 10, 2006. 9.
- Lohr LK. Sunitinib and sorafenib represent new treatment options for renal cell cancer. Hem/Onc Today. June 2006; 6.
- Velcade product information. Millennium Pharmaceuticals, Inc. Cambridge, MA. March 2006.
- Vectibix product information. Amgen, Inc. Thousand Oaks, CA. September 2006.
- Rituxan product information. Biogen IDEC, Inc. and Genentech, Inc. South San Francisco, CA. March 2006.
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/ neu oncogene. Science. 1967;235:177–182.
- Erbitux product information. Imclone Systems Incorporated. Branchburg, NJ. March 2006.
- Slevin M, Payne S. New treatments for colon cancer. Br Med J. 2004;329:124–126.
- Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The new era in the treatment of advanced colorectal cancer patients: The role of monoclonal antibodies. Expert Opin Emerg Drugs. 2006;11(4):665–683.
- Avastin product information. Genentech, Inc. South San Francisco, CA. October 2005.
- Yu JL, Rak JW. Host microenvironment in breast cancer development: Inflammatory and immune cells in tumor angiogenesis and arteriogenesis. Breast Cancer Res. 2003;5(2):83–88.
- Miller KD. E2100: A randomized phase II/III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. May 16, 2005. Scientific presentation: American Society of Clinical Oncologists 41st Annual Meeting, Orlando, Fla.
- Moy B, Goss PE: Lapatinib: Current status and future directions in breast cancer. Oncologist. 2006;11(10):1047–1057.
- Geyer CE, et al. Lapatinib (Tykerb) plus capecitabine delays progression of HER2 positive breast cancer. June 3, 2006. Scientific presentation: American Society of Clinical Oncologists 42nd Annual Meeting, Atlanta, Ga.
- Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107: A selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129–141.